按VISION标准PSMA PET/CT筛查不合格并接受177Lu-PSMA治疗的患者的结局:一项多中心回顾性分析
该多中心回顾性队列研究纳入301例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者,按基线PSMA PET/CT结果分为VISION合格组(272例,90.4%)与筛查不合格组(29例,9.6%)。筛查不合格组≥50% PSA下降率更低(21% vs 50%,P=0.005)、PSA无进展生存期更短(2.1 vs 4.1个月,P=0.023),总生存期有更短趋势(9.6 vs 14.2个月,P=0.16)。作者认为需要改进177Lu-PSMA的患者选择以优化结局。
要点
- 301例中VISION-PET筛查不合格者29例(9.6%),合格者272例(90.4%)。
- 筛查不合格组≥50% PSA下降率为21%,合格组为50%(P=0.005)。
- 筛查不合格组PSA无进展生存期2.1个月,合格组4.1个月(P=0.023)。
核心结论
- VISION-PET筛查不合格患者的结局劣于VISION-PET合格患者。
- 本队列未纳入经局部站点评估预先排除的患者(10%-15%),因此在未经选择的人群中可能有20%-25%的患者为筛查不合格者。
- 需要改进177Lu-PSMA的患者选择以优化结局。
研究设计与样本
- 多中心回顾性队列研究,纳入301例接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌患者。
- 根据基线PSMA PET/CT结果将患者分为VISION合格组(VISION-PET-E)与筛查不合格组(VISION-PET-SF)。
- 比较两组的前列腺特异性抗原(PSA)缓解率、PSA无进展生存期和总生存期。
主要发现
- 301例中VISION-PET-E组272例(90.4%),VISION-PET-SF组29例(9.6%)。
- VISION-PET-SF组≥50% PSA下降率为21%,VISION-PET-E组为50%(P=0.005)。
- VISION-PET-SF组PSA无进展生存期为2.1个月,VISION-PET-E组为4.1个月(P=0.023)。
- VISION-PET-SF组总生存期为9.6个月,VISION-PET-E组为14.2个月,VISION-PET-SF组有更短趋势(P=0.16)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本队列未纳入经局部站点评估预先排除的患者(10%-15%)。
- 原文结论指出需要改进177Lu-PSMA的患者选择以优化结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of the study was to assess the outcome of patients with metastatic castration-resistant prostate cancer treated with 177Lu-prostate-specific membrane antigen (PSMA) who would have been a screen failure (SF) in the VISION trial based on PSMA PET/CT criteria. Methods: We conducted a retrospective multicenter cohort study on 301 patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA. The patients were classified into eligible (VISION-PET-E) and SF (VISION-PET-SF) groups on the basis of the baseline PSMA PET/CT results. Prostate-specific antigen (PSA) response rates, PSA progression-free survival, and overall survival were compared. Results: Of 301 patients, 272 (90.4%) and 29 (9.6%) were VISION-PET-E and VISION-PET-SF, respectively. The VISION-PET-SF patients had a worse rate of ≥50% PSA decline (21% vs. 50%, P = 0.005) and PSA progression-free survival (2.1 vs. 4.1 mo, P = 0.023) and tended to have a shorter overall survival (9.6 vs. 14.2 mo. P = 0.16) than the VISION-PET-E patients. Conclusion: The VISION-PET-SF patients had worse outcomes than the VISION-PET-E patients. Our cohort did not include preexcluded patients (10%-15%) by local site assessments. Thus, 20%-25% of the patients may be SFs in unselected populations. Refinements in patient selection for 177Lu-PSMA are needed to optimize outcomes.
引用
- Hotta M, Gafita A, Czernin J, et al. Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022. PMID: 35273096. doi:10.2967/jnumed.121.263441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。